drugset / Trial / NCT03824535

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

NCT03824535

NaSingle-groupOpen-labelDiagnostic

Summary

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Timeline

Start
2019-02-04
Primary completion
2021-07-30
Completion
2021-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-FDG Diagnostic / imaging agent Intravenous
Subject 18F-FSPG Diagnostic / imaging agent Intravenous

Indications